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Abstract
Background: In 2014 approximately 21,200 patients were diagnosed with oesophageal and gastric cancer in
England and Wales, of whom 37 % underwent planned curative treatments. Potentially curative surgical resection
is associated with significant morbidity and mortality. For operable locally advanced disease, neoadjuvant
chemotherapy (NAC) improves survival over surgery alone. However, NAC carries the risk of toxicity and is
associated with a decrease in physical fitness, which may in turn influence subsequent clinical outcome. Lower
levels of physical fitness are associated with worse outcome following major surgery in general and Upper
Gastrointestinal Surgery (UGI) surgery in particular. Cardiopulmonary exercise testing (CPET) provides an objective
assessment of physical fitness. The aim of this study is to test the hypothesis that NAC prior to upper gastrointestinal
cancer surgery is associated with a decrease in physical fitness and that the magnitude of the change in physical
fitness will predict mortality 1 year following surgery.
Methods: This study is a multi-centre, prospective, blinded, observational cohort study of participants with
oesophageal and gastric cancer scheduled for neoadjuvant cancer treatment (chemo- and chemoradiotherapy)
and surgery. The primary endpoints are physical fitness (oxygen uptake at lactate threshold measured using CPET)
and 1-year mortality following surgery; secondary endpoints include post-operative morbidity (Post-Operative
Morbidity Survey (POMS)) 5 days after surgery and patient related quality of life (EQ-5D-5 L).
Discussion: The principal benefits of this study, if the underlying hypothesis is correct, will be to facilitate better
selection of treatments (e.g. NAC, Surgery) in patients with oesophageal or gastric cancer. It may also be possible
to develop new treatments to reduce the effects of neoadjuvant cancer treatment on physical fitness. These results
will contribute to the design of a large, multi-centre trial to determine whether an in-hospital exercise-training
programme that increases physical fitness leads to improved overall survival.
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Background
Worldwide, oesophageal cancer is the eighth most com-
mon cancer and the sixth most common cause of cancer
death, while gastric cancer is the fifth most common
cancer and third most common cause of cancer-death.
In England and Wales, approximately 21,200 patients
were diagnosed with oesophageal or gastric cancer in
2014, of which 37 % underwent planned curative treat-
ment [1, 2]. Although potentially curative, surgical resec-
tion is attempted in up to 80 % of those patients planned
for curative treatments, however significant morbidity and
mortality is reported. The reported 90-day mortality rates
for oesophagectomy and gastrectomy are 4.4 % and 4.3 %
respectively, with 1-year survival rates between 76.1 % and
78.0 % depending on the site of the primary tumour [1]. A
large updated meta-analysis provides evidence that for op-
erable OG disease neoadjuvant therapies improve survival
over surgery alone [3]. In the UK the MAGIC trial has
resulted in a practice change in favour of neoadjuvant
chemotherapy (NAC) [4]. Treatment with neoadju-
vant therapies carries the risk of toxicity and in
clinical practice this may be associated with an
increased risk of surgical morbidity [3]. Cardiopul-
monary exercise testing (CPET) provides an objective
assessment of physical fitness through evaluating
cardio-respiratory function under the stress of exer-
cise mimicking the stress of major surgery. Variables
derived from CPET such as oxygen uptake at esti-
mated lactate threshold ( _Vo2 at θ^L ) and at peak ex-
ercise ( _Vo2 peak) are associated with worse outcome
following UGI surgery [5, 6].
In a preliminary study, we showed, in a small number of
patients, that neoadjuvant chemotherapy (NAC) before
upper gastrointestinal (UGI) cancer surgery significantly
reduced physical fitness [7]. In this study, lower baseline
fitness was associated with reduced 1-year-survival in pa-
tients completing NAC and surgery, but not in patients
who did not complete NAC. We therefore speculated that
in some patients the harms of NAC may outweigh
the benefits and set out to test the hypothesis that
neo-adjuvant chemotherapy (or chemoradiotherapy)
was associated with reduced physical fitness ( _Vo2 at
θ^L measured using CPET) and that this fall in _Vo2 at
θ^L would in turn be associated with increased harm
(mortality at 1 year) following surgery.
In this manuscript, we describe the design of a pro-
spective, observational, observer blinded cohort study
investigating the effects of neoadjuvant cancer therapies
(both chemo- and chemoradio-therapy – NAC/CRT) on
exercise capacity and clinical outcome in patients under-
going surgery for UGI cancer.
Aims
The aim of this study is to test the hypothesis that the
decrease in physical fitness associated with NAC/CRT
prior to UGI cancer resection may outweigh the benefits
(duration of survival) achieved by NAC/CRT in some
patients. Specifically, we will test the following hypoth-
eses in this patient group:
Primary hypotheses:
1) Neoadjuvant cancer treatment will result in a
decrease in physical fitness ( _Vo2 at θ^L), measured
using CPET.
2) The change in physical fitness ( _Vo2 at θ^L) associated
with neoadjuvant cancer treatment will be associated
with mortality 1 year after surgery. This second
hypothesis will be evaluated in two separate ways:
A) The relative decrease in physical fitness ( _Vo2 at
θ^L) associated with neoadjuvant cancer treatment
prior to UGI cancer resection will be associated
with mortality at 1 year after surgery.
Secondary hypotheses:
B) Patients whose physical fitness ( _Vo2 at θ^L)
changes their risk stratification category (low risk
_Vo2 at θ^L >14 ml.kg.
-1min-1, medium risk _Vo2 at
θ^L 11.0–14.0 ml.kg
-1.min-1, high-risk _Vo2 at θ^L
8.0–10.9 ml.kg-1.min-1, highest risk _Vo2 at θ^L
<8.0 ml.kg-1.min-1) following neoadjuvant cancer
treatment would have an increased 1-year mortality
following surgery when compared with those who
do not increase risk stratification category.
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3) Pre-NAC variables (including CPET derived variables)
can be modelled to predict post NAC _Vo2 at θ^L.
Exploratory hypotheses:
4) The relative decrease in physical fitness ( _Vo2 at θ^L)
associated with neoadjuvant cancer treatment prior
to UGI cancer resection will be associated with i)
increased post-operative morbidity, assessed using
the Post-Operative Morbidity Survey (POMS), and
ii) worse patient reported outcome assessed using
EQ-5D quality of life questionnaire.
5) The relative decrease in peak oxygen consumption
( _Vo2 peak) associated with neoadjuvant cancer
treatment prior to UGI cancer resection will be
associated with i) increased post-operative morbidity,
assessed using POMS, ii) worse patient reported
outcome, assessed using EQ-5D quality of life
questionnaire and iii) decreased 1 year survival.
6) Patients with a lower exercise capacity ( _Vo2 at θ^L and
_Vo2 peak) tolerate NAC prior to upper gastrointestinal
cancer resection (in terms of patient reported outcome
and compliance with NAC protocol) less well than
patients with a higher exercise capacity.
7) Patients who do not tolerate NAC prior to upper
gastrointestinal cancer resection (in terms of
PROMS and compliance with NAC protocol) have a
worse postoperative outcome (1-year mortality,
POMS, EQ-5D).
8) Changes in CPET derived variables will explain
mechanisms of NAC associated exercise limitation.
9) CRT (CROSS style chemoradiotherapy) will result in
a greater fall in _Vo2 at θ^L and _Vo2 peak between
pre- and post- neoadjuvant cancer treatments than
NAC (MAGIC type chemotherapy).
Methods
Design
This study is planned as a multi-centre, prospective,
observational, blinded (for physiological and surgical
outcome assessments) observational cohort study,
funded by the National Institute for Health Research
for Patient Benefit Programme (PB-PG-0609-18262),
approved for all NHS sites by the Dyfed Powys Research
Ethics Committee (11/WA/0072) and registered with
clinicaltrials.gov (NCT01325883). The study is to be
conducted in four United Kingdom based NHS hospi-
tals including; University Hospital Southampton NHS
Foundation Trust, University Hospital Aintree NHS
Foundation Trust, Lancashire Teaching Hospital and
South Tees Hospital NHS Foundation Trust (above
ethics number covers all four NHS sites).
Participants
All patients listed to undergo NAC/CRT followed by
elective UGI cancer resection (oesophagectomy and
gastrectomy) are eligible for inclusion. Exclusion criteria
are: inability to give informed consent, under 16 years of
age, non-resectable disease, inability to perform CPET
or bicycle exercise due to known contra-indication, and
patients who declined surgery or neoadjuvant cancer
treatment, or who received non-standard neoadjuvant
cancer treatment.
Recruitment
Patients who are candidates for curative surgery will
undergo CPET both before and after neoadjuvant
cancer treatment. All potentially eligible patients will
be identified at the UGI multi-disciplinary meeting
and approached with written information about the
trial at the oncology/surgical outpatient appointment.
All patients will be contacted by telephone to provide
additional information about the trial and to confirm
their eligibility. If the patient chooses to participate in
the study, the first research visit is organised and
written informed consent will be obtained together
with all baseline measurements.
Measurements
All patients will undergo a CPET and a patient reported
outcome measure (PROM) questionnaire before neoad-
juvant cancer treatment and also following completion
of neoadjuvant cancer treatment (approximately 4 weeks
following completion of neoadjuvant cancer treatment
and immediately before planned surgery). Other out-
come measures to be assessed following surgery are
summarised in Table 1.
Chemotherapy vs. Chemoradiotherapy
Due to the advent of CRT treatment during the conduct
of this study, an additional hypothesis (number 9 above)
has been added to those proposed in the original study
protocol to explore any differences in impact on physical
fitness between neoadjuvant cancer treatments, namely
NAC (MAGIC type chemotherapy) and CRT (CROSS
style chemoradiotherapy).
Primary outcome
Physical fitness ( _Vo2 at θ^L) derived using CPET
CPET will be used to assess physical fitness pre- and
post-neoadjuvant cancer treatment. Patient and surgical
characteristics recorded at first CPET will include age,
gender, height, weight, diagnosis, staging, planned pro-
cedure. Height and weight will also be recorded at the
second CPET. All CPET’s are performed in-hospital by
trained and experienced staff with full resuscitation cap-
ability. All efforts will be made to conduct the tests to
facilitate other clinical appointments. Each individual
CPET is conducted at a similar time of day. Participants
will be asked to refrain from caffeine ingestion and
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strenuous exercise prior to the test for at least 2 h. All
CPET’s will be performed using an electromagnetically
braked cycle ergometer (Ergoline 2000), 12 lead ECG,
non-invasive blood pressure, pulse oximetry and a meta-
bolic cart (Geratherm Respiratory GmbH, Love Medical
Ltd). Patients were asked to perform an incremental
ramp test to the limit of tolerance and to maintain a cyc-
ling cadence at 55–65 revolutions per minute (rmp)
throughout the test. CPET assesses the amount of oxy-
gen extracted from the inspired gas in a given period of
time, expressed as _Vo2 at θ^L and _Vo2 peak. Ventilatory
equivalents for oxygen and carbon dioxide ( _VE= _Vo2 and
_VE= _Vco2 ) are measurements of the ventilatory require-
ment for a given metabolic rate. Estimation of _Vo2 at θ^L
will be performed using a conventional cluster of vari-
ables (breakpoint in the _Vo2 and _Vco2 relationship),
with increases in _VE= _Vo2 and end-tidal oxygen partial
pressure but no increase in _VE= _Vco2 or fall in end-tidal
carbon dioxide partial pressure PETCO2 [8]. Evaluation
will be undertaken independently by two experienced
assessors, blinded to each other’s assessments, with
disagreement resolved by a third assessor. The multi-
disciplinary team caring for the patients will not be
provided with any information regarding outcome
measures.
Mortality at 1 year
Date of death will be obtained via the National Medical
Information Service.
Secondary outcomes
Physical fitness ( _Vo2 peak) and preoperative risk
categories derived from CPET
CPET derived _Vo2 at θ^L will be to stratify patients into
preoperative risk categories after neoadjuvant cancer
treatment: low risk _Vo2 at θ^L >14.1 ml.kg
-1.min-1; medium
risk _Vo2 at θ^L 11.0–14.0 ml.kg
-1.min-1; high-risk _Vo2 at
θ^L 8.1–10.9 ml.kg
-1.min-1; highest risk _Vo2 at θ^L
<8.0 ml.kg-1.min-1. CPET derived _Vo2 peak will be defined
as the average _Vo2 over the last 30 s of exercise.
Postoperative morbidity
Post-operative morbidity will be objectively recorded
using POMS at day 3, 5, 7 and 15 days following surgery,
in order to explore the relationship between neoadjuvant
cancer treatments, surgery and short-term post-operative
harm. The POMS [9, 10] is a validated measure of short-
term post-operative harm which includes an 18-item tool
that addresses nine domains of morbidity relevant to the
post-surgical patient: pulmonary, infection, renal, gastro-
intestinal, cardiovascular, neurological, wound complica-
tions, haematological and pain. For each domain either
presence or absence of morbidity will be recorded on the
basis of precisely defined clinical criteria.
Patient reported outcomes measure
Patient Reported Outcomes will be described using
EQ-5D-5 L [11], which has been recommended for
use as a generic PROM following major surgery. This
will be measured at several time points; pre- and
post-neoadjuvant cancer treatment, and 30-days and
1-year post-surgery. This questionnaire includes a
health scale and also encompasses the following 5 do-
mains; 1) mobility, 2) self-care, 3) usual activities, 4)
pain/discomfort 5) anxiety/depression.
Data elaboration and statistical analysis
Sample size calculation
Hypothesis 1: A sample of 152 patients would be required
to detect a difference in 1.0 ml.kg.-1.min-1 of _Vo2 at θ^L
using a paired t-test at the 5 % significance level with 90 %
power. This is assuming the standard deviation of the dif-
ference in _Vo2 at θ^L values is 3.8 ml.kg
.-1.min-1. A smaller
sample of 114 patients would provide 80 % power.
Hypothesis 2A: A sample size of 242 is required to de-
tect a difference in 1 year mortality rates of 15 % [30 %
versus 15 %] between the two AT change groups [no
change/deteriorate] using a chi-squared test at the 5 %
significance level with 80 % power, assuming equal num-
bers of patients in both groups. A smaller sample of 104
patients will be able to detect a difference of 23 % [34 %
vs 11 %] with 80 % power.
The aim for hypothesis 2A is to compare the predict-
ive ability of both models to ascertain how prognostic
the relative decrease in exercise capacity is, after adjust-
ing for baseline exercise. Approximately 250 patients are
required to develop reliable prediction models contain-
ing 5 factors [e.g. age, gender, centre, location of tumour,
laparoscopic vs. open]. This is using the “Rule of 10” and
assumes that the 1-year mortality rate is 20 % [conserva-
tive estimate]. Given a 30 % non-completion of NAC
and 2 CPET tests based on Liverpool data, approxi-
mately 360 patients will need to be recruited. With a
smaller sample of 104 patients and 25 % mortality rate,
we can develop reliable prediction models (using stand-
ard methods) that contain fewer factors, e.g. 3. In
addition, we plan to use “penalised” regression models
that are able to contain more factors, even when the
“Rule of 10” is not met [12].
We therefore set out to recruit 250 patients into this
study in 4 centres over 24 months. The volume of eli-
gible patients in these 4 centers is approximately 200 pa-
tients per year. We therefore estimate that the study
recruitment time would take less than 24 months based
on a 66 % recruitment rate (132 patients per year).
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Procedures for data monitoring and entry
Data will be inputted by double-data entry and data val-
idation will take place according to the procedures set
out in the data management plan and data validation
plan. Prior to any statistical analysis, all variables will be
checked for number of missing values, impossible and
improbable values. Impossible and improbable values
will be defined by clinical opinion. Improbable values
will also include values that are outside three standard
deviations of the mean value, any questions regarding
the data will go back to the data manger. Descriptive sta-
tistics will be calculated for all variables and distribu-
tional assumptions checked.
Statistical analysis
Descriptive analyses will be carried out to summarise pa-
tient characteristics. Continuous variables will be presented
as either mean (standard deviation) or median (inter-quar-
tile) as appropriate. The distribution of the continuous var-
iables will be investigated using histograms. Categorical
variables will be presented as frequency (%).
The primary analysis will be a comparison of physical
fitness ( _Vo2 at θ^L ) before and after neoadjuvant cancer
treatment using a paired t-test. Distributional assump-
tions will be assessed using a normal plot. If these are
not met then Wilcoxon matched-pairs signed-ranks test
will be used. Survival at 1 year will be compared be-
tween ‘change in fitness’ groups using either the χ2 test
(or Fisher’s exact test if cell counts are insufficient) or
log-rank test depending on the degree of censoring
throughout the year. Either logistic or Cox regression
methods will be used to investigate the relationship be-
tween fitness and mortality, adjusted for confounders.
The calibration and discrimination of these models will
be assessed. The relationship between morbidity and fit-
ness will be explored using mixed models that account
for the fact that morbidity is measured on several occa-
sions post-surgery.
All estimates will be given with 95 % confidence inter-
vals. Missing data will be investigated though imputation
is not planned as we do not expect a large proportion of
missing data. All analyses will be performed with the
statistical software Stata 14.0.
Discussion
Oesophageal and gastric neoadjuvant cancer treatments
together with surgery have been associated with 1-year
mortality [7]. The reliability and association of CPET
variables with outcome following major surgery has now
been established [13–15]. Selected CPET variables like
the _Vo2 at θ^L and _Vo2 peak have the utility of identify-
ing high-risk surgical patients, prior to a variety of major
surgical procedures. Additionally, other variables derived
from CPET such as the ventilatory equivalent ratio for car-
bon dioxide ( _VE= _Vco2) are associated with post-operative
outcome in several surgical patient groups [16–19].
At present there is little evidence supporting the use
of pre-operative CPET to aid patient’s and clinician’s de-
cisions in relation to surgical risk, especially pertaining
to oesophago-gastric surgery. Furthermore, evidence
supporting pre- and post- cancer therapy CPET prior to
major surgery as a useful risk-stratification and prognos-
tic tool is also very limited. Assessing physical fitness
before neoadjuvant cancer treatment may provide add-
itional information that allows clearer risk-assessment
and risk-mitigation by perioperative physicians. This will
also better assist cancer patients in their decision-
making process and consent. Identification of factors
predictive of the response to neoadjuvant cancer treat-
ment would allow better targeting of cancer treatment
and improve the quality of information informing both
the multi-disciplinary team and patient decisions.
The findings from this study are likely to be of particu-
lar importance in patients with borderline initial fitness
where further loss of fitness after neoadjuvant cancer
treatment may be critical, and in whom over-all survival
may even be improved by proceeding directly to surgery.
The study aims to answer important clinical questions
including;
1. Is neoadjuvant cancer treatment (NAC/CRT)
associated with a reduction in physical fitness before
surgery?
2. In less fit patients, is this reduction related to worse
clinical outcomes (mortality and morbidity)?
3. Is NAC/ CRT associated with a reduction in quality
of life following cancer treatment and before
surgery?
4. Is there an association suggesting that it might be
possible to select patients for NAC/ CRT based on
physical fitness refined using objectively measured
CPET variables?
Strengths of this study include the use of blinded
data collection and analysis, double data entry and
the robust statistical analyses employed. Furthermore,
other strengths of this study include the homogeneous
study population, the clearly defined inclusion and exclu-
sion criteria, the number of contributing centres, the wide
ranging geographical distribution (in an attempt to reduce
bias due to socioeconomic status and geography), the ro-
bust reporting of objectively measured CPET variables,
and the use of the POMS as a primary outcome measure
for morbidity. Additionally, reporting of CPET safety as-
pects, medium term survival follow-up, blinding of the
data analyses and the double data entry further reinforce
the study design.
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Conclusion
The results of this study will inform testing of the above
mentioned hypothesis which might allow individualisa-
tion of the treatment pathway for patients with locally
advanced oesophago-gastric cancers. That might mean
that patients who are unfit have a survival advantage
after surgery if they do not have NAC/CRT. Further-
more, patients would have a tailored risk-stratification
prior to major surgery and therefore would be better in-
formed prior to consenting for cancer major surgery.
The principal benefits of this study, if the underlying hy-
pothesis is correct, will be improved information to cli-
nicians allowing better patient selection for neoadjuvant
cancer therapies and major surgery, together with
informing larger clinical trials aiming to improve clinical
outcomes (reduced mortality and morbidity). Finally, our
group is exploring the effects of tailored preoperative ex-
ercise intervention strategies during and after neoadju-
vant cancer treatments in this patient group to assess
whether increasing preoperative physical fitness may im-
prove postoperative outcome. Tailoring the correct treat-
ment plan to the correct patient may therefore increase
survival. Results of the current study will be available at
the end of 2016.
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